about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersAssessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group studyCombined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group StudyCombination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancerMismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.The impact of body weight on ovarian cancer outcomes.Imaging across the life span: innovations in imaging and therapy for gynecologic cancer.Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivoPerformance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer casesEstrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.Management of a rapidly enlarging new adnexal mass: a rare case of desmoplastic small round cell tumor of the ovary arising in pregnancyA pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's diseaseEndometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.Lynch syndrome.Complications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: time to change back?Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Hysterectomy for the treatment of gynecologic malignancy.Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancer.The Use of Transvaginal Ultrasound in Type II Endometrial Cancer.Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications.Intraoperative radiation therapy (IORT) for gynecologic malignancies.Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy.Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.The role of sentinel lymph nodes in endometrial and cervical cancer.Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation.Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI.Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer.Response to Dr. Carter's letter to the editor regarding "Short and long term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging".Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients.Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging.
P50
Q21144874-6B16B5D4-CC95-40A5-BA97-21A4B9D0A8FAQ30356815-C1B4110F-AEE4-44E9-A013-DBE3D7FCE74AQ30361978-43049559-F5EF-4C10-B8B0-D0F29730A3ECQ33381373-61C5DDED-E5B7-4213-990C-410E14D84427Q33397995-82BE5B68-9514-4438-976F-91B00CD5431BQ34023517-9B62FC3A-9459-43C6-A759-4D6FBBAEFD0EQ34245319-AF09F771-A6AC-42BF-BED9-A78478831514Q35057017-E3891DF6-26CA-42F9-9D1C-3C0FC1B23261Q36032452-79708476-A826-4C18-BDBE-24C23D07F50FQ36094483-7870140B-9F4A-4734-989E-8F2EF5F05F4FQ36930858-B2592744-B5E2-4BB9-A2DF-63794D646100Q36983470-9A530183-190A-410F-B473-106331DA74BCQ37029765-3D23F50E-886E-4DFA-8540-B9778539216AQ37360520-F5C74424-6667-45BF-9154-AE0A5CB1CCD2Q37455633-BF4F5A51-19A7-4AE0-9319-D5CB52335E55Q37728686-AB15A59C-D0C1-44BF-8767-2F0799885E74Q37840389-F4E957C2-E6D5-488E-ADB0-EF2D22DC5147Q37867404-4006326D-3F6C-40A2-A6B2-99E6068C7FB6Q38034599-C0ADE200-3536-4683-9FF1-8CB1F97F46A9Q38103775-4F4052B2-6305-496A-892F-86E5ED5F19C8Q38184407-66F9F479-D359-4903-A605-A03A95F08A4AQ38236051-BBA919C1-22FF-4659-80C4-C6440D145342Q38238732-31CE3918-AAFE-4940-BEAF-C6814CAAED8CQ38262337-DA024665-B32D-4834-AEDC-F79FC3639FA0Q38262343-6FB793AF-F13D-460F-9724-9903F557D744Q38312205-6B8A9D3A-11AB-4592-821D-C459BC5ACD2EQ38376529-EE82755C-EC30-454C-9A2B-C8700C6008CEQ38388678-3B02979E-449B-4A61-A5D7-0650D1094459Q38504628-5010614E-E569-4187-9CED-2A1B0B6925ABQ38511960-D6A4448D-95C3-4B22-AE78-71C264C65C65Q38525722-3F195FB2-5337-402B-93F4-A034F4205296Q38555716-D9D31EF9-EA33-42E7-89AC-A4FCA35977EBQ38583388-5F879B18-E358-4E79-8E3E-3C152A465421Q38666833-0BE64DE8-DA50-42BC-AD5C-012272324AB0Q40071196-1BB55F11-7E4A-43CA-ADA0-47835ECBC369Q40232568-764C1185-2474-471B-B17E-13EE05FFE7C2Q40970974-E89D5F37-C67A-4D38-BB1C-F0ED912C9BE9Q43508255-FE41F588-DBF1-4E45-AE35-06D7098A059EQ44152876-64862C02-E29A-4733-B8F5-0AEFCA51BE0BQ45710471-582EC579-4192-42BD-8A8B-657F7A165ACA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Floor Backes
@ast
Floor Backes
@en
Floor Backes
@es
Floor Backes
@sl
type
label
Floor Backes
@ast
Floor Backes
@en
Floor Backes
@es
Floor Backes
@sl
prefLabel
Floor Backes
@ast
Floor Backes
@en
Floor Backes
@es
Floor Backes
@sl
P106
P1153
24484734400
P31
P496
0000-0002-9225-6913